News - Roche

Filter

Current filters:

Roche

Popular Filters

55 to 79 of 379 results

Roche’s Zelboraf improves survival in melanoma patients with brain metastases

Roche’s Zelboraf improves survival in melanoma patients with brain metastases

21-11-2013

Zelboraf (vemurafenib), an already marketed cancer drug from Swiss pharma major Roche (ROG: SIX), has…

EuropeOncologyPharmaceuticalResearchRocheZelboraf

Roche’s Kadcyla approved in the EU for advanced HER2-positive breast cancer

Roche’s Kadcyla approved in the EU for advanced HER2-positive breast cancer

20-11-2013

Swiss drug major Roche says that Kadcyla (ado-trastuzumab emtansine or T-DM1), the latest targeted medicine…

EuropeKadcylaOncologyPharmaceuticalRegulationRoche

EMA finds no new safety concerns following Roche pharmacovigilance inspection

EMA finds no new safety concerns following Roche pharmacovigilance inspection

19-11-2013

The European Medicines Agency has finalized a thorough review of all medicines manufactured by Swiss…

EuropePharmaceuticalRegulationRoche

IQWiG says no added benefit for Roche’s Erivedge has been proven

IQWiG says no added benefit for Roche’s Erivedge has been proven

18-11-2013

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products…

ErivedgeEuropeOncologyPharmaceuticalPricingRegulationRoche

Report looks at impact of new law governing clinical trials in Switzerland

Report looks at impact of new law governing clinical trials in Switzerland

15-11-2013

Clinical trials in Switzerland have been the subject of a new report carried out by the Swiss Federal…

Basilea PharmaceuticaEli LillyEuropeLegalNovartisPharmaceuticalResearchRoche

Japan NHI price listing for Chugai’s Kadcyla delayed

14-11-2013

Japanese drugmaker Chugai Pharmaceutical, which is majority owned by Swiss major Roche, says that the…

Asia-PacificChugai PharmaceuticalKadcylaOncologyPharmaceuticalPricingResearchRoche

Roche and immatics ink mega-million cancer vaccine and immunotherapy deal

Roche and immatics ink mega-million cancer vaccine and immunotherapy deal

13-11-2013

Germany’s privately-held immatics biotechnologies GmbH and Swiss drug major Roche have entered into…

BiotechnologyIMA942immatics biotechnologiesImmunologicalsOncologyRocheVaccines

Chugai unit seals deal for Helsinn’s anamorelin in top EU markets

12-11-2013

Privately-held Swiss pharmaceutical group Helsinn has granted Chugai Pharma Marketing, a wholly-owned…

anamorelinChugai PharmaceuticalEuropeHelsinnLicensingOncologyPharmaceuticalRoche

Roche’s Gazyva slows disease worsening compared to MabThera/Rituxan

Roche’s Gazyva slows disease worsening compared to MabThera/Rituxan

07-11-2013

Swiss drug major Roche (ROG: SIX) has announced new data from the second stage of the CLL11 Phase III…

EuropeGazyvaMabTheraOncologyPharmaceuticalResearchRituxanRoche

Report: Tarceva and Iressa favored by European oncologists for NSCLC

Report: Tarceva and Iressa favored by European oncologists for NSCLC

04-11-2013

Oncologists across the top five European countries are prescribing Roche's Tarceva or AstraZeneca's Iressa…

AstraZenecaEuropeIressaOncologyPfizerPharmaceuticalPricingRegulationRocheTarcevaXalkori

Roche’s Gazyva gains FDA approval of CLL

Roche’s Gazyva gains FDA approval of CLL

04-11-2013

The US Food and Drug Administration late Friday approved Roche’s Gazyva (obinutuzumab), also known…

Biogen IdecBiotechnologyGazyvaGenentechMabTheraNorth AmericaobinutuzumabOncologyRegulationRituxanRoche

Roche in-licenses POL7080 from Polyphor in up to 500 million-franc accord

Roche in-licenses POL7080 from Polyphor in up to 500 million-franc accord

04-11-2013

Drug major Roche has entered into an exclusive worldwide license agreement to develop and commercialize…

Antibiotics and Infectious diseasesLicensingPharmaceuticalPOL7080PolyphorRoche

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report

30-10-2013

Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

Roche and Chugai’s SC RoActemra improves RA long term

Roche and Chugai’s SC RoActemra improves RA long term

28-10-2013

Roche and its majority-owned Japanese subsidiary Chugai Pharmaceutical have announced that their RoActemra…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalPharmaceuticalResearchRoActemraRoche

European prescribing attitudes for rheumatoid arthritis post-ADACTA

European prescribing attitudes for rheumatoid arthritis post-ADACTA

28-10-2013

Results from the ADACTA trial, which showed that Swiss drug major Roche’s RoActemra (tocilizumab) is…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyEuropeHumiraMarkets & MarketingPfizerRoActemraRochetofactinib

Genentech’s SC Actemra approved by US FDA for severe RA

Genentech’s SC Actemra approved by US FDA for severe RA

22-10-2013

Genentech has announced that the US Food and Drug Administration has approved a subcutaneous formulation…

ActemraAnti-Arthritics/RheumaticsGenentechNorth AmericaPharmaceuticalRegulationRoche

Roche investing 800 million Swiss francs to expand biologics production

Roche investing 800 million Swiss francs to expand biologics production

14-10-2013

Roche said this morning it plans to invest 800 million Swiss francs ($879.2 million) within its global…

BiotechnologyEuropeFinancialGenentechKadcylaNorth AmericaPerjetaProductionRoActemraRoche

UK NICE final draft guidance on treatment for chronic hepatitis C

UK NICE final draft guidance on treatment for chronic hepatitis C

11-10-2013

The UK drugs watchdog the National Institute of Health and Care Excellence this morning confirmed its…

Anti-viralsEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferon

UK’s NICE thumbs up for Roche drug in rare autoimmune disease in draft guidance

UK’s NICE thumbs up for Roche drug in rare autoimmune disease in draft guidance

03-10-2013

The UK’s drugs watchdog, the National Institute for Health and Care Excellence (NICE) has published…

EuropeMabTheraOncologyPharmaceuticalPricingRegulationRoche

US nephrologists views on prescribing Roche’s Mircera

02-10-2013

Among surveyed US nephrologists, familiarity with Swiss drug major Roche's Mircera is low, but is still…

InjectaferKeryx BiopharmaceuticalsMirceraNeurologicalNorth AmericaPharmaceuticalRocheZerenex

Roche highlights late-stage pipeline beyond cancer

02-10-2013

Swiss drug major Roche has provided an update from its leading late-stage pipeline comprising 10 new…

Gastro-intestinalsKadcylalampalizumabOncologyOphthalmicsPharmaceuticalResearchRoche

More highlights from European Cancer Congress from Boehringer and Roche

More highlights from European Cancer Congress from Boehringer and Roche

30-09-2013

Roche presented new results from a trial of an investigational antibody which have shown encouraging…

Boehringer IngelheimEuropeHerceptinnintedanibOncologyPharmaceuticalResearchRoche

55 to 79 of 379 results

Back to top